For experts

Become our expert

We are looking to cooperate with experts to be engaged in R&D expert review of VC projects associated with new developments of pharmaceuticals and technologies in the field of medicine.

Cooperation with external experts is subject to a paid basis.

To participate in R&D expert review activities the experts must obtain accreditation (see below).

The work with experts is based on the following:

Accredited experts subject to the expert review shall assess a scientific value of the VC project under review for potential investment pursuant to standard terms of reference. Impersonal consolidated expert report shall be generated following the results of assessment.

For more information concerning R&D expert review process in RusnanoMedInvest, LLC please go here.  

Major expert enrollment criteria:

  1. Over 7 years of experience in R&D (scientific field - pharma, life sciences,  medicine)  or medical (physician) practice
  2. Academic degree (at least Doctor of Science is a plus)
  3. Academic rank (Professor is a plus)
  4. Publications in peer-reviewed journals / in international journals / # of monographs or books (personal or in co-authorship)
  5. Membership in professional associations, communities, awards other professional achievements
  6. Level of English (documents for the expert review are provided in English)


To join our expert team:

  1. Please fill in the application
  2.  Sign the application, scan and send using the form to send messages: 

The right to verify information provided is vested in RusnanoMedInvest, LLC.

Please note that filled form is not subject to instant accreditation as an expert. 

The contract on the expertise is offered by D-Pharma LTD – the management company of RusnanoMedInvest.


All Partners

All Portfolio


  • Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines

    Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines

    Pfizer Inc, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio. The deal will enable Pfizer and NovaMedica to improve the health of patients in Russia and modernize the Russian pharmaceutical industry.

All news